Author + information
- Received February 29, 2016
- Revision received November 16, 2016
- Accepted December 16, 2016
- Published online April 17, 2017.
- Dariusz Dudek, MD, PhDa,∗ (, )
- Łukasz Rzeszutko, MD, PhDb,
- Yoshinobu Onuma, MD, PhDc,
- Yohei Sotomi, MDd,
- Rafał Depukatb,
- Susan Veldhof, RNe,
- Divine Ediebah, MSe,
- Peter Staehr, MDf,
- Wojciech Zasada, MD, PhDg,
- Krzysztof P. Malinowski, MSh,
- Grzegorz L. Kaluza, MD, PhDi and
- Patrick W. Serruys, MD, PhDj
- aJagiellonian University Institute of Cardiology, Krakow, Poland
- bUniversity Hospital, Krakow, Poland
- cThoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
- dAcademic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
- eAbbott Vascular, Diegem, Belgium
- fAbbott Vascular, Santa Clara, California
- gKrakow Cardiovascular Research Institute, Krakow, Poland
- hJagiellonian University Medical College, Krakow, Poland
- iCardiovascular Research Foundation, Orangeburg, New York
- jInternational Center for Circulatory Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
- ↵∗Address for correspondence:
Dr. Dariusz Dudek, Jagiellonian University Institute of Cardiology, Kopernika 17th Strasse, Krakow 31-501, Poland.
Objectives This study investigated the vasomotor response to nitroglycerine (NTG) up to 5 years after ABSORB implantation.
Background There are no data regarding long-term vasomotor response after everolimus-eluting bioresorbable vascular scaffold ABSORB implantation.
Methods We performed quantitative coronary angiography of the scaffolded and proximal and distal adjacent segments of patients from ABSORB Cohort B study before and after 200 μg of intracoronary NTG at 2, 3, and 5 years of follow-up. The mean changes of maximal and mean lumen diameters in the scaffolded and adjacent segments were calculated.
Results The mean in-scaffold lumen diameter change in response to NTG showed a trend to increase over time with absolute values of 0.03 ± 0.09 mm, 0.05 ± 0.12 mm, and 0.07 ± 0.08 mm at 2, 3, and 5 years, respectively (p = 0.40). The maximal in-scaffold lumen diameter change significantly increased with values of 0.03 ± 0.14 mm, 0.06 ± 0.16 mm, and 0.11 ± 0.1 mm at 2, 3, and 5 years, respectively (p = 0.03). The normalized mean lumen diameter change after NTG in the scaffold relative to the adjacent segments was 51.9 ± 54.8% at 5 years of follow-up (p = 0.60).
Conclusions Although there was a numerical increase of the vasomotor response to NTG after ABSORB implantation measured by quantitative coronary angiography with mean lumen diameter, the change was not statistically significant. However, the maximal lumen diameter changes increased over time from 2 to 5 years and attained statistical significance. The vasomotor response to NTG after ABSORB implantation moderately trended to increase, which is consistent with the progressive degradation and bioresorption of the scaffold, but the degree of vasomotor response remained lower in comparison with adjacent segments.
Drs. Dudek, Rzeszutko, and Depukat have received Investigator grants during the progress of the study from Abbott Vascular. Drs. Onuma and Serruys are members of the Abbott Vascular Advisory Board. Drs. Ediebah, Staehr, and Veldhof are full-time employees of Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Drs. Dudek and Rzeszutko contributed equally to this work and are joint first authors.
- Received February 29, 2016.
- Revision received November 16, 2016.
- Accepted December 16, 2016.
- 2017 American College of Cardiology Foundation